How PwC turns “corporate antibodies” into allies: Five tactics to try
By Patricia Riedman Yeager, Contributing Writer
As most readers of Innovation Leader are painfully aware, the death of good ideas at the hands of business units — sometimes referred to as “organ rejection” — is a common problem. In fact, according to our 2015 Innovation Benchmarking Report, published last year with innovation consultancy Innosight, 50 percent of respondents said that innovation projects typically get axed because of insufficient business unit buy-in.
But for many companies, it’s not just business-unit leaders who are obstacles to innovation: It’s other individuals in the system who are there to protect a company from risk — like the legal or compliance departments.... continued ...